While annual reports show broadly similar R&D strategies among Merck & Co., Pfizer, Johnson & Johnson and AbbVie, their 2020–2023 financial metrics reveal a concerning trend. Merck & Co. may be the new top dog of Big Pharma, but the firm’s 1.4% revenue growth in 2023 represents a significant slowdown. Pfizer’s 41.7% revenue decline from…
Big Pharma shakeup: This chart reveals the new top dog of 2023
In the Aesopian fable, the tortoise’s steady focus and persistence overcomes the hare’s bursts of speed. 2023 saw a similar shift in the pharma sector. While Pfizer, thanks to blockbuster COVID vaccine sales, rocketed to unprecedented heights in 2022 surpassing $100 billion in revenue, its fortunes reversed in 2023. As COVID product demand plummeted, Pfizer’s…
Pharma M&A activity primed for another high-flying year in 2024
Despite challenging interest rates and regulatory environment, pharma M&A activity surged in 2023 with deal volume up more than 30% from the prior year based on a review of more than 200 acquisitions since 2018. The total disclosed deal value in 2023 also more than doubled the prior year’s tally to surpass $100 billion. While…
A glimpse at Big Pharma’s upper echelon in the first three quarters of 2023
In 2023, demand for GLP-1 receptor agonists such as Lilly’s tirzepatitde and Novo Nordisk’s semaglutide surged just as demand for COVID-19 therapies waned. As a result, Novo Nordisk had 33% growth at constant exchange rates over the first nine months of the year. Similarly, Lilly experienced a 37% jump in revenue in the third quarter,…
Quantum computing promises new frontier in drug discovery and bioinformatics
Quantum computing — described by pop astrophysicist Neil deGrasse Tyson as “computing with atoms” — is an emerging technology with a potential for immense computational speed and power. For some problems, quantum computers can be exponentially faster than classical computers, while for others the speedup may be more measured. The promise for drug discovery could…
Big Pharma, it’s time to talk: Investors demand transparency on patent thickets
Pharmaceutical companies are running into pushback for their “patent thicket” tactics, designed to maintain exclusive rights and delay cheaper generics. The Financial Times reported that an ethical investor coalition is pushing for greater transparency and urging major drug makers to disclose their patent strategies. Unraveling the patent thicket mystery Patent thickets are a common intellectual property…
Big Pharma companies trimming pipelines in 2023
Several companies, including GSK, Janssen, Novartis and Pfizer, have announced that they are cutting their pipelines as they release their full-year 2022 financial results. The following are the drugs removed from these companies’ pipelines. Bristol Myers Squibb Anti-CTLA-4 NF: The oncology monoclonal antibody candidate directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) known as BMS-986218 was…
Why Big Pharma is partnering with startups as it becomes more data-driven
Big Pharma’s ability to innovate has grown in recent years, and the industry’s increasing reliance on data could help it sustain momentum in the future. While McKinsey notes that the industry has been relatively slow in adopting technologies such as AI and automation, the industry is growing more tech-savvy. “The acceptance of data is picking up across…
As interest in psychedelic medicine grows, Big Pharma sits on the sidelines
While Big Pharma has yet to embrace psychedelics as potential treatments for depression and other psychiatric disorders, interest in psychedelic medicine is building. Earlier this month, Nature Medicine published a Phase 3 study indicating that psychotherapy assisted with methylenedioxymethamphetamine (MDMA) was a more effective treatment for post-traumatic stress disorder (PTSD) than therapy alone. The study authors concluded…
Debate series considers the therapeutic promise and pitfalls of psychedelics
Intelligence Squared, the organizers of a popular debate series, recently asked a panel of experts whether psychedelics should be legalized. There was considerable overlap between the factions arguing in favor and opposition of that motion, reflecting the growing interest in psychedelic compounds for therapeutic applications. But the two camps were split when it came to…